Discovery of gastric inhibitory polypeptide (GIP) Among those active in the field was John Brown (figure 16), a British-born physiologist, who developed a passion for the gastrointestinal gut while doing a doctorate at the University of Newcastle-upon-Type
The drugs can have unsavory side effects, most frequently nausea
These can include nausea, constipation, diarrhea, reflux, bloating, decreased appetite, abdominal discomfort, or vomiting
Overall, across PBMs the consensus access policy is very tight : PBMs uniformly require prior authorization for GLP-1s used for obesity, almost always mandate step therapy, and site-of-care is typically limited (e.g
1,188 GLP-1 reduces hepatic glucose production, partly by inhibiting the expression and activity of key gluconeogenic enzymes
International GLP-1 pricing comparisons: Peterson-KFF Health System Tracker